Unlike endorepellin, which has no direct effects on cancer cells, decorin also binds EGFR and Met receptors expressed on tumor parenchyma and inhibits tumor growth and development through stunting proliferation and angiogenesis while activating mitophagy (107, 108, 109). This evidence concerns the gene HSPG2 and neoplasm.